We currently have 22 clinical development programs, with about 28,000 patients enrolled in more than 100 Celgene-sponsored clinical trials. At the same time we are mindful that Celgene is part of an ecosystem of innovation. Our research and discovery efforts seek to collaborate with and complement the work of medical and academic institutions of excellence, government agencies and regulators, patient advocacy groups and non-governmental organizations, as well as investors and other biopharmaceutical companies.
A strong commitment to five pillars of corporate responsibility permeate our global organization: patients and communities, commitment to safety, governance, global health and environment and sustainability. Let me cite just a few highlights. Our commitment to patients extends beyond our innovative life-enhancing therapies to our pioneering patient access programs. Our Patient Support Coordinators work tirelessly to help patients gain access to the treatments they need. More than 20,000 patients have received assistance from Celgene Patient Support since 2007.
Our giving centers on patient-focused programs such as the Leukemia and Lymphoma Society’s Light the Night walks, where Celgene ranked first among biopharmaceutical companies, and the Pancreatic Cancer Action Network’s Purple Strides campaign. Our focus also extends to supporting science education through our participation in programs like Change the Equation, as well as scholarships and fellowships to help train the next generation great minds in the life sciences.
For the complete report and more: http://assets1.celgene.com/content/uploads/celgene-responsibility.pdf